ProCE Banner Activity

Testing the Boundaries of 2-Drug ART: Early Data on Efficacy and Safety for Rapid ART

Conference Coverage
Clinical Thought
Preliminary evidence from the open-label STAT study suggests that the 2-drug regimen DTG/3TC may be a safe and effective choice for rapid-start ART. Here’s my take on what we learned from this HIV Glasgow report.

Released: December 04, 2020

Expiration: December 03, 2021

Share

Faculty

Eric S. Daar

Eric S. Daar, MD

Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Educational grant provided by:

Gilead

Janssen Therapeutics Division of Janssen Products

ViiV Healthcare

Faculty Disclosure

Primary Author

Eric S. Daar, MD

Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Eric S. Daar, MD, has disclosed that he has received consulting fees from Genentech, Gilead Sciences, and ViiV and funds for research support from Gilead Sciences, Merck, and ViiV.